SDC1 and Miyoshi myopathy: The viable (i.e., TOPRO-3 negative) CD138+ cell fraction was significantly reduced in BM samples from macitentan-treated mice as compared to controls (11 vs 44%, p=0.001) (Figure 2A), thus showing that macitentan can reach effective therapeutic concentrations in the tissue primarily affected by MM cell expansion.